Wakuda Hiroyuki, Aoki Ryota, Nakakura Shunsuke
Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji 671-1227, Japan.
J Clin Med. 2024 Oct 15;13(20):6132. doi: 10.3390/jcm13206132.
: This study aimed to evaluate the postoperative outcomes of the PreserFlo MicroShunt in Asian patients with exfoliation glaucoma. : We used the Kaplan-Meier method to analyze 29 eyes of 29 patients with exfoliation glaucoma (mean age: 80.7 ± 8.3 years; 16 males; 24 eyes with intraocular lens implants; preoperative intraocular pressure [IOP]: 32.5 ± 9.3 mmHg; preoperative antiglaucoma medications: 3.4 ± 1.0; Asian ethnicity: 100%) who underwent PreserFlo MicroShunt surgery alone at Saneikai Tsukazaki Hospital from November 2022 to November 2023. The criteria for survival were a reduction in IOP of ≥20%, no additional glaucoma surgery, and IOP of 5-21 mmHg (condition 1), 5-18 mmHg (condition 2), and 5-15 mmHg (condition 3). Needling and glaucoma eye drops were considered qualified successes. : The mean follow-up period was 27.9 weeks, with a reoperation rate of 31% (9 cases). The complete and qualified success survival rates at 24 weeks were 56%, 52%, and 49%, and 67%, 59%, and 53% for conditions 1-3, respectively. The complete and qualified success survival rates at 48 weeks were 47%, 43%, and 45%, and 52%, 46%, and 48% for conditions 1-3, respectively. : The postoperative outcomes of the PreserFlo MicroShunt in Asian patients with exfoliation glaucoma demonstrated an approximate 50% success rate at both 24 and 48 weeks, with a reoperation rate of approximately 30%. Caution is warranted when performing PreserFlo MicroShunt in patients with exfoliation glaucoma.
本研究旨在评估PreserFlo微型分流器在亚洲剥脱性青光眼患者中的术后效果。我们采用Kaplan-Meier方法分析了2022年11月至2023年11月在冢崎 saneikai医院仅接受PreserFlo微型分流器手术的29例剥脱性青光眼患者的29只眼睛（平均年龄：80.7±8.3岁；男性16例；24只眼睛植入了人工晶状体；术前眼压[IOP]：32.5±9.3 mmHg；术前抗青光眼药物：3.4±1.0；亚洲人种：100%）。生存标准为眼压降低≥20%、未进行额外的青光眼手术且眼压为5-21 mmHg（条件1）、5-18 mmHg（条件2）和5-15 mmHg（条件3）。针刺和青光眼眼药水被视为合格的成功案例。平均随访期为27.9周，再次手术率为31%（9例）。条件1-3在24周时的完全成功和合格成功生存率分别为56%、52%和49%，以及67%、59%和53%。条件1-3在48周时的完全成功和合格成功生存率分别为47%、43%和45%，以及52%、46%和48%。PreserFlo微型分流器在亚洲剥脱性青光眼患者中的术后效果显示，在24周和48周时成功率约为50%，再次手术率约为30%。对剥脱性青光眼患者进行PreserFlo微型分流器手术时需谨慎。
